SynthesisBMC nephrology2025
Combination therapy with mineralocorticoid receptor antagonists and SGLT2 inhibitors versus SGLT2 inhibitor monotherapy in chronic kidney disease: an updated meta-analysis of randomized controlled trials.
Synthesis in BMC nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChronic kidney disease (CKD) affects millions worldwide and poses a major healthcare challenge. While both sodium-glucose co-transporter 2 (SGLT2) inhibitors and mineralocorticoid receptor antagonists (MRAs) or aldosterone synthase inhibitors (ASIs) have shown individual benefits in CKD, data on their combined use remain limited. This study examined the safety and efficacy of combining an SGLT2 inhibitor with an MRA or ASI compared to SGLT2 inhibitor monotherapy.
methodsA comprehensive search was conducted on PubMed, Cochrane (CENTRAL), ScienceDirect, and Embase for randomized controlled trials (RCTs) comparing combination therapy with an MRA or ASI and an SGLT2 inhibitor with SGLT2 inhibitor monotherapy in patients with CKD. Continuous and dichotomous outcomes were pooled as Mean Difference (MD) or Risk Ratio (RR), respectively, with 95% Confidence Intervals (CIs) using Review Manager (v5.4.1.), and heterogeneity was assessed using the I² statistic.
resultsFive RCTs (n = 808 patients) were included. Combination therapy significantly reduced albuminuria (MD: -32.82% [95% CI: -39.16, -26.48] %; p < 0.001), systolic blood pressure (MD: -5.02 mm Hg [95% CI: -6.95, -3.08] mm Hg; p < 0.001), and estimated glomerular filtration rate (MD: -2.59 mL/min/1.73 m2 [95% CI: −3.78, − 1.40] mL/min/1.73 m2; p < 0.001). While the risk of hyperkalemia was higher (RR: 1.91 [95% CI: 1.10,3.33]; p = 0.02) with combination therapy, no significant differences were found in serious adverse events (RR: 0.95 [95% CI: 0.57,1.59]; p = 0.86).
conclusionThe combination therapy provides added renal and cardiovascular benefits in CKD without increasing serious adverse effects. These findings support its superior therapeutic potential and highlight the need for large-scale, prospective studies to assess long-term effects on hard renal and cardiovascular outcomes. PROSPERO REGISTRATION: CRD420251106173.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.